Paper: Combination Immunotherapy Approaches

BMT Tandem "Scientific" Meeting

Seaport A-E (Manchester Grand Hyatt)

Charles Drake, MD, PhD , Johns Hopkins University, Baltimore, MD

Disclosures:

C. Drake, Bristol Myers Squibb: Consultancy , Research Funding and Royalty
Compugen: Consultancy and Ownership Interest
Dendreon: Consultancy
ImmunExcite: Consultancy and Ownership Interest
NexImmune: Consultancy and Ownership Interest
Novartis, NA: Consultancy
Pontenza Therapeutics, NA: Consultancy and Ownership Interest
Janssen: Consultancy and Research Funding
Aduro Biotech, NA: Research Funding

See more of: Checkpoint Inhibitors
See more of: BMT Tandem "Scientific" Meeting

<< Previous Presentation | Next Presentation >>